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Abstract
Background: Tuberculosis (TB) and tobacco use are two major alarming global health issues that tend to be
co-prevalent in many developing countries and various surveys have provided evidence on their entangled
associations. Accordingly, it is strongly suggested that smoking cessation be incorporated in TB control programs.
Therefore, we aimed to evaluate the effectiveness of two smoking cessation methods among newly-diagnosed
pulmonary TB patients.
Methods: A total of 210 newly-diagnosed pulmonary TB patients from Tehran, Iran with smoking habits were
included in this randomized clinical trial during 2012–2013. Patients were assigned to three groups of control
(just TB medical treatment), brief advice (TB medical treatment plus individualized counseling sessions of quitting
behavioral therapy) and combined intervention (TB medical treatment plus individualized counseling sessions of
quitting behavioral therapy plus medical treatment with slow release bupropion). Patients’ abstinence was
followed at six time point during six months. Data were analyzed by SPSS v.22 using Generalized Estimating
Equations (GEE) model.
Results: Abstinance rate at the end of six months were 71.7 % for combined intervention group, 33.9 % for brief
advice group and 9.8 % for the control group (p < 0.001). Combined intervention group and brief advice group
respectively had 35 times (p < 0.001, OR = 35.26, 95 % CI = 13.77–90.32) and 7 times (p < 0.001, OR = 7.14, 95 % CI = 2.
72–18.72) more odds of not being an active smoker at each time point, compared to the control group.
Conclusion: Considering the prevalence and importance of TB and the substantial influence of these preventive
measures on controlling tobacco use, application of such programs is recommended.
Trial registration: The survey was registered in the Iranian registry of clinical trials website (irct.ir) in August 31, 2013
with IRCT ID: IRCT2013062613783N1.
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Background
Tuberculosis (TB) and tobacco use are two major
alarming global health issues posing immense threats
to human populations [1, 2]. The annual mortalities re-
lated to these two epidemics are currently estimated to
exceed seven million people [2]. TB and tobacco smok-
ing tend to be co-prevalent and many developing
countries are shouldering the concurrent burdens of
the two outbreaks, simultaneously [3, 4]. Furthermore,
various surveys have provided evidence on the relation
between tobacco use and TB disease. Cigarette smoking
is found to be associated not only with TB disease and
tuberculous infection, but also with delayed bacterio-
logic clearance, increased susceptibility to infection, re-
currence and TB related deaths [5–10]. The prevalence
of smoking has also been found to be higher among TB
patients compared to control groups and normal popu-
lations [11–15].
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Tobacco smoking is associated with decreased proin-
flammatory cytokine release, decreased level of immuno-
globulins in blood circulation and decreased CD4+ to
CD8+ ratio causing suppression of both cell mediated
and humoral mediated immunities that can lead to TB
infection and improper treatment response [16–19]. The
immunological changes are reported to be reversed
within 6 weeks of quitting.
Although conventionally all the physicians suggest that
their patients quit smoking, no separate counseling ses-
sions are held specially for this important issue and most
physicians just briefly mention the benefits of smoking
cessation. Accordingly, it is strongly suggested that smok-
ing cessation be incorporated in tobacco control programs
[3]. Various behavioral methods have been proposed for
smoking cessation in TB patients such as brief advice,
which has been proven to considerably increase the rate
of smoking cessation in these subjects [20]. International
Union Against Tuberculosis and Lung Disease has pro-
posed different methods of implementing brief advice,
which have conformed to one concise easy method ac-
cording to the national guidelines of United States of
America [21]. Another method known as combined inter-
vention has also been developed which embodies both
simplified counseling models involving brief advice and
pharmaceutical treatments [4, 14]. This method has also
been found to be effective on smoking cessation of the
evaluated subjects.
These simple interventions can provide vital informa-
tion for TB patients on the necessity of prevention from
exposure to tobacco smoke, without the need for com-
plicated and costly measures. However, in spite of the
urgent need, most specialists and medical staff are not
familiar with these services [22].
Despite the available evidence on the effects of educa-
tional interventions on smoking cessation in TB patients
[20, 21, 23–26], further investigations are required to
find the best program for this means. Therefore, consid-
ering the correlation between smoking and TB disease
and the importance of quitting in pulmonary TB pa-
tients, for the first time in Iran, this study aimed to
evaluate the effectiveness of smoking cessation methods
among newly-diagnosed pulmonary TB patients.
Methods
This study was conducted during December 2012 to
February 2014 on newly-diagnosed smear positive pul-
monary TB patients with smoking habits to evaluate the
effects of two smoking cessation methods. Eligibility re-
garding the patients’ smoking status was assessed ac-
cording to self-declaration of subjects based on the
guidelines of World Health Organization and Inter-
national Union Against Tuberculosis and Lung Disease
[5]. Inclusion criteria were as follows:
 Newly-diagnosed pulmonary TB patients according
to a positive sputum smear (based on treatment
guideline of WHO) [27]
 Patients classified as Category I (newly-diagnosed
TB patients)
 Aged 18 years or older
 Persian speaking patients
Exclusion criteria included:
 Extra-pulmonary TB (brain, pericardium, adrenal
glands, etc.)
 Multi drug resistance
 Co-infection with HIV/AIDS
 Opium addiction
 Patients classified as Category II (recurrence,
treatment failure or treatment errors)
 Patients classified as Category III (chronic TB)
 Contraindications for treatment with bupropion
 Not willing to participate
 Unable to communicate and comprehend the
written consent form
The study was designed on the basis of a homoge-
neous sample population and since following up patients
with newly-diagnosed TB was more convenient, this
group was chosen as the target population and patients
with extra-pulmonary TB were excluded. Moreover,
most HIV positive patients are IV drug abusers and are
known to use various drugs; hence, inclusion of these
patients might have led to inclusion of multiple con-
founding factors into our survey so we decided to ex-
clude these patients as well. Patients with resistant TBs
were also excluded due to their prolonged treatment
course and long-term follow ups which were not com-
patible with this survey’s design. Category II and III pa-
tients were also excluded since their follow up trends
were incompatible with our study’s protocols.
Sampling
The city of Tehran (capital of Iran) was divided into
three districts regarding the coverage of health centers
by each of the three medical universities. Two health
centers implementing the Directly Observed Treatment
Short Course (DOTS) strategy were chosen from each
district, according to the population covered by the cen-
ters and their consent for participation. 1530 TB patients
referring to the six selected health centers or the referral
hospital of Masih Daneshvari during December 2012 to
February 2014 were evaluated and 210 newly-diagnosed
pulmonary TB patients with positive smoking habits
were enrolled in this study.
Using random permuted block numbers and stratifying
according to age, gender and nationality, the included
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subjects were randomly assigned to three groups of com-
bined intervention, brief advice and control.
Data collection and interventions
In their first session all the patients included were evalu-
ated regarding their tobacco use status, history of smok-
ing, nicotine dependency (based on Fagerstrom test),
reasons for smoking (based on WHO standard tests),
the extent to which they were willing to quit (based on
the trans-theoretical model [5]: pre-contemplation, con-
templation, preparation, action and maintenance) and
motivation for quitting.
The control group just received the DOTS regimen,
while the other two groups participated in educational
interventions additional to the DOTS course. During the
first two weeks, the patients assigned to the brief advice
group participated in 4 sessions of smoking cessation
counseling based on behavioral therapy. The interven-
tion was designed according to the manual of smoking
cessation interventions for TB patients [26], through
which necessary information about the benefits of quit-
ting considering their underlying disease were explained
clearly for the subjects.
The 5A’s protocol including Ask, Advise, Assess, Assist
and Arrange [5] was utilized for the combined interven-
tion group. In the first two weeks four counseling ses-
sions were held giving each patient personalized
consultations including behavioral therapy for quitting.
The educational intervention was based on the manual
of smoking cessation interventions for TB patients [26].
All the subjects were also treated by slow release bupro-
pion (wellban ER, Abidi) given 150 mg/d in the first
week followed by 300 mg/d till the end of the ninth
week. All the medical treatments and counseling ses-
sions for all the three groups of control, brief advice and
combined intervention were delivered by one trained
physician in each center.
Finally smoking cessation was evaluated in all three
groups by assessing the expiratory carbon monoxide
(CO) concentration via PICO Smokerlysers device (Bed-
font Scientific Maidstone, UK) based on standard criteria
[28]. Exhaled CO level was evaluated 6 times for each
patient at the end of the second, third and fourth coun-
seling sessions in the first two weeks, in the second
month follow up session and at the end of the fourth
and sixth month follow-ups. Patients were categorized
into two group based on the level of their exhaled CO
level at each time point in a way that patients with an
exhaled CO level of less than 7 ppm were considered as
nonsmokers and subjects with a CO level of higher than
7 ppm were categorized as smokers. These assessments
were performed by a different physician in each center,
blinded to the patients’ groups.
Statistical analysis
The data were entered into SPSS (v.20) and checked for
outliers. In order to check that the distribution of demo-
graphic and smoking-related characteristics were not
statistically different in the study groups, Chi-squared
test (e.g. for sex and marital status) and one way ANOVA
(e.g. for smoking initiation age, quit motivation score)
were used. Then, as the study groups were found homoge-
neous according to these factors, to evaluate the effects of
smoking cessation methods in newly-diagnosed pulmon-
ary tuberculosis patients, Generalized Estimating Equa-
tions (GEE) model with binary outcome was used to take
the time differences into account. Moreover, various struc-
tures (unstructured, independent …) were evaluated for
the correlation matrix and the model with the lowest
Quasi-Akaike Information Criterion (QIC) and the best
goodness-of-fit was applied as the final model.
Ethical considerations
All the necessary information was thoroughly explained
for the eligible patients and from the subjects willing to
participate in the survey, an informed written consent
was obtained. The study methods were approved by the
Research Ethics Committee of Tuberculosis and Lung
Disease research center and the Ethics Committee of
Shahid Beheshti University of Medical Sciences. The sur-
vey was registered in the Iranian registry of clinical trials
website (irct.ir) in August 31, 2013 with IRCT ID:
IRCT2013062613783N1.
Results
Two hundred and ten newly-diagnosed patients were
found eligible to be included in the survey, of which 27
were excluded later due to a delayed positive HIV test,
opium abuse, moving to another place to follow their
treatment, lack of proper adherence to bupropion treat-
ment and inaccessibility of the subject. Finally 60 pa-
tients were assigned to the combined intervention group,
62 subjects to the brief advice group and 61 patients to
the control group (Fig. 1).
On allocation, subjects were stratified according to age
for sex and nationality. However, statistical analyses were
also performed on all the characteristics of the subjects
including age, living area, education and occupation to
ensure the randomization of allocation. The results were
quite close to each other and no significant intergroup
difference was found regarding demographic characteris-
tics of the subjects (Table 1).
Tobacco use related factors did not differ significantly
between the three groups. The mean number of ciga-
rettes smoked daily was 15.30, 15.66 and 17.01 among
the control group, brief advice group and combined
intervention group respectively (p = 0.62). The rate of
contemplation for quitting within the next month was
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found to be 42.6, 46.8 and 45 % for the same arrange-
ment of groups (p = 0.89) and the mean score of motiv-
ation from 10, was calculated to be 5.57, 5.10 and 5.51
(p = 0.43), respectively (Table 2). Compliance with TB
therapy was also found to be similar in the three groups.
Considering the trend of changes in rate of smoking
cessation from the third day through the end of the sixth
month, combined intervention group was found to
present with significantly higher figures (p < 0.001) (Fig. 2).
Evaluation of continuous cessation at the end of the sec-
ond month found a considerably higher rate in the com-
bined intervention group with 78.3 % compared to the
brief advice group with 38.7 % and the control group with
11.5 % (p < 0.001) (Table 3). Assessment after 6 months
Fig. 1 Details regarding total number of eligible patients and breakdown of reasons for exclusion
Table 1 Demographic characteristics of the subjects in each group recruited from Tehran, Iran during 2012–2013
Demographic factor Control Brief advice Combine intervention p-value
sex Male 55 (90.2 %) 56 (90.3 %) 54 (90.0 %) 0.99
Female 6 (9.7 %) 6 (9.7 %) 6 (10.0 %)
Age 47.36 ± 16.30 45.53 ± 16.43 45.05 ± 15.81 0.78
Nation Iranian 53 (86.9 %) 50 (80.6 %) 54 (90.0 %) 0.32
Afghan 8 (13.1 %) 12 (19.4 %) 6 (10.0 %)
Marital status Single 24 (39.3 %) 27 (43.5 %) 25 (41.7 %) 0.89
Married 37 (60.7 %) 35 (56.5 %) 35 (58.3 %)
Living area Urban 38 (62.3 %) 38 (61.3) 43 (71.7 %) 0.32
Rural 23 (37.7 %) 24 (38.7 %) 17 (28.3 %)
Education Illiterate 10 (16.4 %) 14 (22.6 %) 9 (15.0 %) 0.62
Under diploma 31 (50.8 %) 34 (54.8 %) 35 (58.3 %)
Diploma and academic 20 (32.8 %) 14 (22.6 %) 16 (26.7 %)
Job Manual 18 (29.5 %) 23 (37.1 %) 29 (48.3 %) 0.10
Office-worker 43 (70.5) 39 (62.9 %) 31 (51.7 %)
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yielded similar results with 71.7 % for the combined inter-
vention group, 33.9 % for the brief advice group and 9.8 %
for the control group and the differences were found to be
statistically significant (p < 0.001) (Table 3).
Since analyses (Chi-Square test for qualitative variables
and Kruskal-Wallis for quantitative variables) performed
on smoking-related variables including age of onset,
smoking status, reason for smoking, number cigarettes
per day, history of quitting, motivation for quitting, con-
templation for quitting, pack year, and Fagerstrom score
did not found any significant difference, they were ex-
cluded and only the variables of age, nationality, marital
status, location, education and occupation were included
in modeling.
Finally through GEE analysis, the rates of not being
an active smoker at each time point were assessed in
the three groups taking multiple observations at differ-
ent times into account and controlling for confounding
factors. The total quit differences were statistically
significant in the groups (p < 0.001). As resulted, the pa-
tients in combined intervention group and brief advice
group respectively had 35 times (p < 0.001, OR = 35.26,
95 % CI = 13.77–90.32) and 7 times (p < 0.001, OR =
7.14, 95 % CI = 2.72–18.72) more odds of not being an
active smoker at each time point compared to the con-
trol group.
Discussion
Tobacco use and tuberculosis have been described as an
epidemic twisted skein. Tobacco use, is considered as
one of the most important health risk factors in the
countries in which smoking has become epidemic and
along with tuberculosis, these health issues have become
extensively prevalent in these regions [3].
In their mathematical model, Basu et al. estimated
that a strict control on tobacco use leading to a 1 % an-
nual decrease in prevalence of smoking can prevent 27
million smoking- and TB-related deaths till 2050. On
Table 2 Smoking-related characteristics of the newly-diagnosed PTB patients recruited from Tehran, Iran during 2012–2013
Factor Control Brief advice Combine intervention p-value
Smoking initiation age 21.77 ± 7.43 22.26 ± 9.47 22.67 ± 9.90 0.94
Smoking status
Daily 55 (90.2 %) 59 (95.2 %) 55 (91.7 %) 0.56
Occasional 6 (9.8 %) 3 (4.8 %) 5 (8.3 %)
Smoking Cause
Relaxation 7 (11.7 %) 6 (9.8 %) 2 (3.3 %) 0.47
Enjoyment 0 (0 %) 2 (3.3 %) 2 (3.3 %)
Addiction 25 (41.7 %) 29 (47.5 %) 30 (50.0 %)
Habitual 28 (46.7 %) 24 (39.3 %) 26 (43.0 %)
Number of daily cigarettes 15.30 ± 10.45 15.66 ± 10.98 17.02 ± 10.87 0.62
PYa 20.02 ± 17.39 20.04 ± 20.58 22.11 ± 21.19 0.89
Fgb 6.43 ± 2.88 5.76 ± 2.47 6.71 ± 2.54 0.6
Hookah consumption
Yes 15 (24.6 %) 14 (22.6 %) 16 (26.7 %) 0.38
No 46 (75.4 %) 48 (77.4 %) 44 (73.3 %)
Previous quit attempts
Yes 39 (63.9 %) 35 (56.5 %) 34 (56.7 %) 0.63
No 22 (36.1 %) 27 (43.5 %) 26 (43.3 %)
Intention to quit
Yes 40 (65.6 %) 42 (67.7 %) 34 (56.7 %) 0.41
No 21 (34.4 %) 20 (32.3 %) 26 (43.3 %)
Intention to quit in next month 26 (42.6 %) 29 (46.8 %) 27 (45.0 %) 0.89
35 (57.4 %) 33 (53.2 %) 33 (55 %)
Quit motivation 6.31 ± 2.38 6.18 ± 2.71 6.58 ± 2.34 0.67
Quit insurance 5.57 ± 2.36 5.10 ± 2.47 5.51 ± 2.31 0.43
Pre intervention Pico 7.49 ± 2.23 7.17 ± 2.30 7.66 ± 2.19 0.53
aPack/Year: calculated by multiplying the number of packs of cigarettes smoked per day by the number of years the subject has smoked
bFagerstrom score: a scale for measuring nicotine dependency
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the other hand, a 50 % rise of tobacco use among adult
population (a phenomenon observed in countries with
high prevalence of smoking) can add 34 million extra
TB-related deaths till 2050 [29].
The results of the present survey showed that implemen-
tation of a combined intervention for newly-diagnosed
smear positive pulmonary TB patients can lead to a signifi-
cant increase (71.7 %) in the rate of continuous smoking
cessation at the end of sixth months. Moreover, a brief ad-
vice intervention was also found to increase this rate to a
considerable figure of 33.9 % compared to 9.8 % in the
control group. Based on the logistic regression analysis
carried out, these two interventions, compared to the con-
trol group, can increase the odds of not being an active
smoker at each time point by 35 and 7 times, respectively.
This figure, particularly for the combined intervention
group, was significantly higher than the observations of
Siddiqi et al. in Pakistan [24]. They showed that behavioral
support in combination with bupropion increased the rate
of continuous smoking cessation after 6 months to 45.4 %,
compared to 41 % for behavioral support alone and 8.5 %
for the control group. In their survey behavioral support
comprised of two counseling sessions and bupropion
was administered with a dose of 150 mg/d for seven
weeks. Patients were evaluated after 1, 5 and 25 weeks.
The different results might be due to the disagreements
between the two surveys regarding their methods; 2
counseling sessions vs. 4, and 7 weeks of 150 mg/d bu-
propion vs. 9 weeks of 300 mg/d bupropion in our
study. Also the evaluation checkpoints differed between
the two studies. Moreover, they included the patients
suspected to have TB while our study population com-
prised of TB patients with definite diagnoses and so
our results can more appropriately be generalized to
the whole population of TB patients being treated by
DOTS course.
The study conducted by Awaisu et al. in Malaysia
reported higher figures than ours. At their 6 month
evaluation, 77.5 % of the patients in the intervention
group (behavioral therapy combined with nicotine re-
placement therapy) and 8.7 % of the patients in the
control group were found to be in a 4 month con-
tinuous smoking cessation. In their survey, new TB
cases with positive or negative smear results who
were motivated to quit within the next 30 days of
TB diagnosis were assigned to the intervention group
with 11 counseling sessions and patients in the stages
of pre-contemplation and contemplation were put
into the control group [23]. The fact that they in-
cluded patients that are already willing to quit in the
next 30 days might be the reason for their higher
yielded efficacy.
Fig. 2 The trends of changes in smoking cessation status in the three groups of the newly-diagnosed PTB patients recruited from Tehran, Iran
during 2012–2013
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Campbell et al. assessed the effectiveness of brief ad-
vice in TB patients in Nepal and found that 39 % of
their intervention group managed to be smoke free in
6 months while none of their control subjects were able
to stay clean in that period [30]. In the study conducted
by Siddiquea et al. in Bangladesh, 82 % of the subjects
declared that they had not smoked in 6 months and the
rate of smoking cessation was reported to be higher
among pulmonary TB patients compared to extra-
pulmonary TB cases [25]. El sony et al. aimed to evalu-
ate the effects of repeated brief advice interventions on
smoking cessation among new pulmonary TB patients
in Sudan. In their survey, 47 % of patients declared that
they had not smoked in 6 months. However, they only
assessed male subjects and no biochemical validation of
smoking cessation was carried out [20].
Stead et al. evaluated 41 trials conducted on normal
smoker populations and found that brief advice can
significantly increase the rate of quitting (RR = 1.66).
They also found complete intervention to be more ef-
fective than brief advice for this means (RR = 1.37)
[31]. However, it should be noted that being diag-
nosed with TB and the patient being ill, can be
enough on its own to motivate the patient to quit
[32–34] and this can be the reason for the better
results yielded from implementing smoking cessation
interventions on TB patients.
In our study we included patients of both genders but
as reported, the majority of our study population was
male. Although, the results can still be generalized to
the whole population since the proportion of male to fe-
male in our sample population is quite similar to the fig-
ure reported for the smokers in the whole Iranian
population [35] and the considerably lower prevalence
of smoking among females led to inclusion of mostly
male subjects in this study.
The discrepancies observed between the mentioned
studies can be attributed to the variabilities in the design
of the surveys, their study populations, the outcomes
measured and the time at which they are evaluated.
However, all these studies showed significant improve-
ments in smoking cessation rates after various cessation
programs and interventions.
As mentioned, tobacco use can increase the prevalence
of TB and its related mortalities and so strict control
over smoking can prevent millions of TB related deaths.
Accordingly, the need for inclusion of smoking cessation
measures in TB control programs seems undeniable.
This survey paved the way for further investigations on
this matter and provided evidence supporting the need
Table 3 The trend of changes in smoking cessation status in the three groups of the newly-diagnosed PTB patients recruited from




Control (61 cases) Brief Advice (62 cases) Combined intervention (60 cases) p-value
N (%) N (%) N (%)
Session 2
Quit 4 (6.6 %) 20 (32.3 %) 25 (41.7 %) <0.001
Smoker 57 (93.4 %) 42 (67.7 %) 35 (58.3 %)
Session 3
Quit 4 (6.6 %) 20 (32.3 %) 43 (71.7 %) <0.001
Smoker 57 (93.4 %) 42 (67.7 %) 17 (28.3 %)
Session 4
Quit 7 (11.5 %) 25 (40.3 %) 47 (78.3 %) <0.001
Smoker 54 (88.5 %) 37 (59.7 %) 13 (21.7 %)
Month 2
Quit 7 (11.5 %) 24 (38.7 %) 47 (78.3 %) <0.001
Smoker 54 (88.5 %) 38 (61.3 %) 13 (21.7 %)
Month 4
Quit 7 (11.5 %) 22 (35.5 %) 46 (76.7 %) <0.001
Smoker 54 (88.5 %) 40 (64.5 %) 14 (23.3 %)
Month 6
Quit 6 (9.8 %) 21 (33.9 %) 43 (71.7 %) <0.001
Smoker 55 (90.2 %) 41 (66.1 %) 17 (28.3 %)
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to establish smoking cessation clinics in TB control
health centers.
One of the limitations of this study was that we only
measured the outcome of smoking cessation in these pa-
tients until the end of TB treatment, while previous
studies have shown that many patients start smoking
again after completing their TB therapy [15]. This might
over-estimate the effects of evaluated cessation measures
in quitting since patients tend to take smoking cessation
more seriously when it is concurrent with their TB treat-
ments and although the adverse effects of smoking and
the utmost importance of complete continuous cessation
are thoroughly explained to them, they might ignore
these facts and start smoking again. Moreover, it has
been shown that smoking is a risk factor for relapse of
TB disease in patients with successful treatments which
increases the costs and imposes additional burdens to
the public health systems. Therefore, further investiga-
tions are required to assess the long-term outcomes of
these cessation programs even particularly after comple-
tion of TB treatments.
Furthermore, we used the expiratory carbon monoxide
concentration to confirm smoking status of the subjects
which is not an absolute indicator of smoking status. So
it is recommended that future studies incorporate urine
cotinine and nicotine derivatives as their outcome mea-
sures to yield more reliable results.
Conclusion
Putting it all together, regarding the smoking related mor-
bidities and mortalities of TB patients and considering the
significant effects of educational interventions provided as
combined method or brief advice, it seems logical to in-
clude these measures as a part of TB control programs.
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